Introduction
Reinfection with rubella may occur and has been reported after both naturally acquired and vaccine induced infection. Reinfection is usually subclinical and is detected serologically, most commonly among pregnant women who have had close and prolonged contact with rubella at home. Reinfection in pregnancy has been considered to present a minimal risk to the fetus, and mothers are usually reassured that there is no risk or only a minimal one to the fetus.' 2 Nevertheless, there have been several isolated reports of fetal infection and malformation resulting from maternal reinfection (reviewed by Morgan-Capner3). We report five such cases.
Patients and methods
Cases were referred by obstetricians, paediatricians, and microbiologists or were identified from reports to the Communicable Disease Surveillance Centre by laboratories in England and Wales during 1985-8. Standard techniques were used for serological testing of mothers and infants and for isolating rubella virus from the products of conception or from throat swabs taken from infants.4 When possible the avidity of specific IgGl was measured; high avidity suggests recent reinfection.'
Results
The table shows details of the five cases; all five women were without symptoms throughout pregnancy. Three women (cases 1-3) were serologically investigated after contact with rubella between four and eight weeks' gestation, when their children had symptoms like rubella. IgM antibody (specific for rubella) was detected in serum samples taken from all three women after contact; subsequent samples from two of them (cases 1 and 2) showed a decline in titre. Reinfection was diagnosed because antibody had been detected by radial haemolysis at >15 000 IU/l on two occasions before the affected pregnancy; these serum samples were not available for retesting. The the doctor or manufacturer of the vaccine could not be considered to have been negligent. Nevertheless, unless a no fault compensation scheme is established such cases are likely to entail parents in considerable expense over a prolonged period and create considerable adverse publicity for rubella vaccination. Indeed, this has occurred recently; it would be unfortunate if such adverse publicity destroys the public's confidence in a remarkably effective and safe vaccine. The selective rubella vaccination programme in the United Kingdom was recently augmented by the introduction of a combined measles, mumps, and rubella vaccine for children of both sexes. 8 Although this programme will reduce the circulation of rubella in the community and thereby decrease the risk of exposure of pregnant women to the virus, cases of reinfection will probably continue to be diagnosed for some years. Until rubella infection is eradicated consideration must be given to showed an association between starting treatment and resolution of the fever. In three patients the upward trend in temperature continued despite treatment and reversed only with an increasing granulocyte count >1l0 x 109/1. The trend was most easily interpreted with either 37-6°C or the mean of the first six temperature points during the fever as the reference. In five patients the cusum distribution showed clearly that the temperature trend was improving; further antimicrobial agents, however, had been given on the basis of a perceived non-response from the conventional temperature charts ( figure.) 
